Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices 71581 

is invited to provide comment on the 

current Healthy People 2030 objectives 

and propose additional core, 

developmental, or research objectives 

for consideration that address critical 

public health issues. Proposed new 

objectives must meet all the objective 

selection criteria (see below). The public 

is also invited to propose new topics to 

be considered for inclusion in Healthy 

People 2030. 

Objective Selection Criteria 

Core Objectives 

Core objectives must meet the 

following five criteria to be included in 

Healthy People 2030. Core objectives 

should (1) have a reliable, nationally 

representative data source with baseline 

data no older than 2015; (2) have at least 

two additional data points beyond the 

baseline during the decade; (3) be of 

national importance; (4) have effective, 

evidence-based interventions available 

to achieve the objective; and (5) have 

data to help address disparities and 

achieve health equity. 

Developmental Objectives 

Developmental objectives will have 

the following characteristics: (1) 

represent high priority issues; (2) do not 

have reliable baseline data yet; and (3) 

have evidence-based interventions 

available. 

Research Objectives 

Research objectives will have the 

following characteristics: (1) represent 

key opportunities to make progress in 

areas with limited prior research, a high 

health or economic burden, or 

significant disparities between 

population groups; (2) may or may not 

have reliable baseline data; and (3) do 

not have evidence-based interventions 

available. 

Written comments and evidencebased information should be submitted 

by email to HP2030Comment@hhs.gov 

by 11:59 p.m. ET on November 20, 2023. 

Comments received in response to this 

notice will be reviewed and considered 

by the Healthy People topic area 

workgroups, Federal Interagency 

Workgroup on Healthy People 2030, and 

other Federal subject matter experts. 

Paul Reed, 

Deputy Assistant Secretary for Health, Office 

of Disease Prevention and Health Promotion. 

[FR Doc. 2023–22805 Filed 10–16–23; 8:45 am] 

BILLING CODE 4150–32–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Speech, Language, and Motor 

Function. 

Date: November 8, 2023. 

Time: 10:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Louise Hargrave, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

Bethesda, MD 20892, (301) 443–7193, 

hargravesl@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: The Cancer Biotherapeutics 

Development (CBD). 

Date: November 13–14, 2023. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Laurie Ann Shuman Moss, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 867–5309, laurie.shumanmoss@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Musculoskeletal, Orthopedic, Oral, 

Dermatology and Rheumatology. 

Date: November 15–16, 2023. 

Time: 8:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aftab A. Ansari, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4108, 

MSC 7814, Bethesda, MD 20892, (301) 237– 

9931, ansaria@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–22– 

180: Maximizing Investigators’ Research 

Award (MIRA) (R35-Clinical Trial Optional). 

Date: November 15–16, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Heidi B. Friedman, Ph.D., 

Senior Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 907–H, 

Bethesda, MD 20892, (301) 379–5632, 

hfriedman@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Arthritis, Connective Tissue and 

Skin. 

Date: November 15, 2023. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard Michael Lovering, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1000J, 

Bethesda, MD 20892, (301) 867–5309, 

loveringrm@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cell and Developmental Biology of 

Eye. 

Date: November 15, 2023. 

Time: 2:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rass M. Shayiq, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

2359, shayiqr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: The Cancer Drug Development and 

Therapeutics (CDDT). 

Date: November 16–17, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lilia Topol, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6192, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0131, ltopol@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Instrumentation, Environmental, 

and Occupational Safety. 


lotter on DSK11XQN23PROD with NOTICES1
71582 Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices 

Date: November 16–17, 2023. 

Time: 9:30 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Joonil Seog, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–402–9791, joonil.seog@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Computational, Modeling, and 

Biodata Management. 

Date: November 16, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 6188, MSC 

7804, Bethesda, MD 20892, 301–435–1267, 

belangerm@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 12, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22859 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Botulinum Toxin Potency 

Assay using Tissue Chips. 

Date: November 20, 2023. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, One Democracy Plaza, 6701 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rahat (Rani) Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892, 301–594–7319, 

khanr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: October 12, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22858 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN Initiative: Centers for Engineering 

Molecular Technologies for Functional 

Dissection of Neural Circuits (UM1). 

Date: November 17, 2023. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Jasenka Borzan, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Neuroscience Center, 

Bethesda, MD 20892, 301–435–1260, 

jasenka.borzan@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: October 11, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22804 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention’s 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on December 5, 2023, from 

10 a.m. EST to 4:30 p.m. 

The board will meet in open-session 

December 5, 2023, from 10 a.m. EST to 

4:30 p.m. EST to hear Federal Partner 

updates and presentations regarding 

NLCP activities, updates to the MRO 

manuals, lab created cannabinoids and 

other contaminants in commercially 

available products and the process for 

adding or removing analytes from the 

analyte table for federally regulated 

testing. The board will discuss the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs and 

updates to the analyte table to include 

Fentanyl. Additionally the Department 

is asking for public comments on the 

recommendation of adding fentanyl/ 

nor-fentanyl to the analyte table. 

Section 8105 of the Fighting Opioid 

Abuse in Transportation Act, included 

in the SUPPORT for Patients and 

Communities Act, required the 

Secretary to determine whether it is 

justified, based on the reliability and 

cost-effectiveness of testing, to revise 

the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs to 

include fentanyl. Section 8105 

additionally required the Secretary to 

consider whether to include any other 

drugs or other substances listed in 

Schedule I and II of Controlled 

Substances Act (CSA). Norfentanyl is a 

metabolite of fentanyl. Because it is also 

an immediate precursor used in the 

illicit manufacture of fentanyl, it is a 

Schedule II substance under the CSA. 


lotter on DSK11XQN23PROD with NOTICES1